117296-93-2

Usage

Uses

Used in Pharmaceutical Industry:
1-[2-(chloromethyl)phenyl]-1H-imidazole is used as an antifungal medication for treating infections caused by fungi on the skin and mucous membranes. It works by inhibiting the growth of fungi, providing effective relief from symptoms associated with fungal infections.
Used in Dermatology:
1-[2-(chloromethyl)phenyl]-1H-imidazole is used as a topical treatment for skin infections caused by fungi. Its antifungal properties help in reducing inflammation, itching, and other discomforts caused by fungal overgrowth on the skin.
Used in Gynecology:
1-[2-(chloromethyl)phenyl]-1H-imidazole is used as a treatment for vaginal yeast infections. Its effectiveness in inhibiting fungal growth makes it a popular choice for managing and alleviating symptoms of vaginal yeast infections.

Upstream product

• 25373-56-2 (2-imidazol-1-yl-phenyl)-methanol 
• 394-35-4 methyl 2-fluorobenzoate 
• 246046-82-2 2-Imidazol-1-yl-benzoic acid methyl ester 

Downstream Products

• 117323-65-6 2-[2-(2-Imidazol-1-yl-benzylsulfanyl)-imidazol-1-yl]-pyridine 

Relevant academic research and scientific papers

2-[(2-Aminobenzyl)sulfinyl]-1-(2-pyridyl)-1,4,5,6- tetrahydrocyclopent[d]imidazoles as a novel class of gastric H+/K+-ATPase inhibitors

Substituted 2-sulfinylimidazoles were synthesized and investigated as potential inhibitors of gastric H+/K+-ATPase. The 4,5-unsubstituted imidazole series 6-11 and the 1,4,5,6-tetrahydrocyclopent[d]imidazole series 12 were found to be potent inhibitors of the acid secretory enzyme H+/K+- ATPase. Structure-activity relationships indicate that the substitution of 2- pyridyl groups at the 1-position of the imidazole moiety combined with (2- aminobenzyl)sulfinyl groups at the 2-position leads to highly active compounds with a favorable chemical stability. Other substitution patterns in the imidazole moiety result in reducing biological activities. 2-[(2- Aminobenzyl)sulfinyl]-1-[2-(3-methylpyridyl)]-1,4,5,6- tetrahydrocyclopent[d]imidazole (12h, T-776) was selected for further development as a potential clinical candidate. Extensive study on the acid degradation of 12h indicates a mechanism of action different from that of omeprazole, the first H+/K+-ATPase inhibitor introduced to the market.